Novo Nordisk A/S

Postdoc for Novel Transcriptome Determination in Cardiometabolic Diseases

Novo Nordisk A/S

Oxford, United Kingdom

About Novo Nordisk Research Centre Oxford (NNRCO)
NNRCO is a new academic-industrial translational hybrid research institute focused on biology and target discovery related to type 2 diabetes and cardiometabolic diseases. NNRCO will interface with the world-leading academic research community of type 2 diabetes and cardiometabolic diseases at Oxford University. NNRCO is a transformational research unit within Novo Nordisk, operating with flexibility and freedom, while being an integral part of the Novo Nordisk Global Drug Discovery Unit. Please see more about Novo Nordisk R&D at:

About the Department
The Discovery Technologies and Genomics Department at NNRCO will play a significant role in target discovery efforts for treatment of type 2 diabetes and cardiometabolic diseases (drug target identification, drug target validation as well as qualification of drug targets). The department establishes and applies state-of-the-art technologies to discover new therapeutic targets for cardio-metabolic diseases.

The Position
We are looking to expand our department with a highly skilled postdoc who could help us making translational discovery and projects in Oxford. The primary objective is to develop and apply molecular biology techniques in RNA sequencing and cell biology to explore new areas of the biology of cardiometabolic diseases: to explore novel sequencing strategies for targeted classes of RNAs and discover novel targets for cardiometabolic diseases.

You will work with a highly creative approach to cellular and molecular questions in human cell culture systems including primary cells, multicellular models and difficult to culture cell lines. You will coordinate your work across multiple groups within NNRCO: Bioinformatics, automation and genomics will all be employed to tackle this task.

It will also be your responsibility to ensure excellence in the laboratory, conducting and following strict methodologies with high precision and a careful approach to work, keeping accurate laboratory records of work. It will also be part of your work to ensure compliance with company guidelines in health and safety regulations.

Finally, you will drive the key decision making for the strategy required for a successful characterization of targeted classes of RNA for cardiometabolic diseases.

The position is temporary for 36 months.

You have a PhD in Cellular and Molecular Biology or equivalent as well as some experience with laboratory work, such as cell culture (primary cells and/or cell lines), cellular assays, western blot, cell fraction, immunoprecipitation, cell function evaluation and keeping of laboratory notebooks.

Moreover, you have some experience in generation of next generation sequencing data. Familiarity with analysis is not required but it will be an advantage. Some knowledge of working in a GMO laboratory will likewise be an advantage. The job requires proficiency in English and excellent communication/collaboration skills

A successful candidate will show a positive “can-do” attitude; be flexible, open to new ideas, ambitious, and results oriented; and thrive in a team in a highly dynamic and fast pace environment.

It is expected for the project to generate results to be published and presented in international scientific conferences.

For information, contact recruitment consultant Nana Fernanda Nielsen at Nana Nielsen at +45 3077 6105 (available until 19th December).

6th January 2020

Please apply via recruiter’s website.

Quote Reference: 21436